12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersCyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shar
BenzingaApr 30 08:06 ET
Vaccinex Files to Sell 193,000 Shares of Common Stock for Holders
Seeking AlphaApr 26 17:32 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersProcessa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC
BenzingaApr 25 08:06 ET
Vaccinex(VCNX.US) 10% Shareholder Buys US$1,333.86 in Common Stock
$Vaccinex(VCNX.US)$ 10% Shareholder FRIEDBERG ALBERT purchased 282 shares of common stock on Apr 19, 2024 at an average price of $4.73 for a total value of $1,333.86. This transaction involves other r
moomoo NewsApr 22 17:16 ET
Vaccinex Faces Nasdaq Compliance Challenge
InvestingApr 12 16:44 ET
Express News | Vaccinex Q4 EPS $(0.33) Up From $(23.10) YoY
Moomoo 24/7Apr 2 22:59 ET
Vaccinex Files to Sell 433.5K Common Shares for Holders
Seeking AlphaApr 2 16:21 ET
Vaccinex Reports Q4 Results
Seeking AlphaApr 2 10:09 ET
Express News | Vaccinex Expects Topline Data For Phase 1/2a Randomized SIGNAL-AD Study Of Pepinemab For Alzheimer's Disease In Q3 2024
Moomoo 24/7Apr 2 08:45 ET
Express News | Vaccinex FY23 EPS $(43.68) Up From $(98.05) YoY, Revenue $570K Up From $275K YoY
Moomoo 24/7Apr 2 08:44 ET
Vaccinex 2023 Rev $570,000 >VCNX
Vaccinex 2023 Rev $570,000 >VCNX
Dow JonesApr 2 08:32 ET
Press Release: Vaccinex Reports 2023 Financial Results and Provides Corporate Update
Vaccinex Reports 2023 Financial Results and Provides Corporate Update Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024 Company raised $17
Dow JonesApr 2 08:30 ET
Express News | Vaccinex, Inc. Announces $1.5M Registered Direct Offering And Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Moomoo 24/7Mar 27 08:31 ET
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's
GlobeNewswireMar 27 08:30 ET
Vaccinex CFO Scott Royer to Retire, Jill Sanchez Steps in
InvestingMar 4 16:40 ET
Sector Update: Health Care Stocks Slipping Wednesday Afternoon
Health care stocks were easing Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both down about 0.4%. The iShares Biotechnology ETF (IBB) fell 0.3
MT NewswiresFeb 21 13:54 ET
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform
Vaccinex (VCNX) shares rose 9.3% in recent trading Wednesday after the biotech company announced eight new agreements allowing the use of its proprietary ActivMAb platform in discovering antibodies ag
MT NewswiresFeb 21 11:31 ET
Teladoc Health, Avinger Among Healthcare Movers
Seeking AlphaFeb 21 10:00 ET
Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology
Eight new antibody discovery agreements incorporate Vaccinex's powerful ActivMAb Drug Discovery Platform ActivMab platform enables the discovery and development of high value antibodies against challe
GlobeNewswireFeb 21 08:00 ET
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Moomoo 24/7Feb 20 08:55 ET
No Data
No Data